Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 25 July, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

Fundamental Analysis of Glenmark Pharmaceuticals Ltd

About the Company - Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 18/11/1977 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24299MH1977PLC019982 and registration number is 019982. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 8141.58 Cr. and Equity Capital is Rs. 28.22 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsB/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai Maharashtra 400026csr@glenmarkpharma.com
http://www.glenmarkpharma.com
Management
NamePosition Held
Mr. Glenn SaldanhaChairman & Managing Director
Mrs. Cherylann PintoExecutive Director - Corporate Affairs
Mr. V S ManiExecutive Director & Global CFO
Mr. Rajesh V DesaiInd. Non-Executive Director
Dr. Brian W TempestInd. Non-Executive Director
Mr. Dipankar BhattacharjeeInd. Non-Executive Director
Mr. Bernard MunosInd. Non-Executive Director
Mr. Sridhar GorthiInd. Non-Executive Director
Mrs. Vijayalakshmi IyerInd. Non-Executive Director
Mr. D R MehtaInd. Non-Executive Director
Ms. Saira RamasastryInd. Non-Executive Director
Mrs. B E SaldanhaNon Executive Director

Basic Stock Data of Glenmark Pharmaceuticals Ltd

Last Updated: July 24, 2024, 11:16 pm

Market Cap 40,244 Cr.
Current Price 1,426
High / Low1,448/702
Stock P/E
Book Value 278
Dividend Yield0.18 %
ROCE12.4 %
ROE32.3 %
Face Value 1.00
PEG Ratio0.00

Data Source: screener.in

Competitors of Glenmark Pharmaceuticals Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Murae Organisor Ltd 36.3 Cr. 1.473.10/0.90727 2.260.00 %0.79 %0.13 % 2.00
Dipna Pharmachem Ltd 18.3 Cr. 7.6024.1/7.4616.8 15.60.00 %8.49 %4.47 % 10.0
Decipher Labs Ltd 18.5 Cr. 18.325.8/14.4 21.60.00 %4.30 %7.46 % 10.0
Coral Laboratories Ltd 250 Cr. 700748/24515.7 4970.00 %12.6 %9.58 % 10.0
Concord Drugs Ltd 38.4 Cr. 38.461.5/28.291.4 33.80.00 %4.54 %1.29 % 10.0
Industry Average21,119.50 Cr1,332.8260.54207.980.35%17.48%16.81%6.54

Glenmark Pharmaceuticals Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales2,7872,8602,9653,1473,1733,0192,7773,0183,1003,3743,0363,2072,507
Expenses2,2572,3362,3912,5572,4802,5562,3462,5392,6262,7692,5992,7452,715
Operating Profit530523574590693463432479474605437462-209
OPM %19%18%19%19%22%15%16%16%15%18%14%14%-8%
Other Income29859-13-1642518386209-840-32-20587
Interest958376696787608397109112121134
Depreciation115111113123119132147146152147142141147
Profit before tax348338444385343270408337435-491151-6-403
Tax %29%31%31%29%30%36%48%17%33%18%-14%-997%18%
Net Profit248234307275240173211279291-403173-62-331
EPS in Rs8.798.2910.869.137.865.516.829.239.66-15.185.31-2.90-12.45

Last Updated: July 10, 2024, 5:21 pm

Glenmark Pharmaceuticals Ltd Quarterly Chart

Glenmark Pharmaceuticals Ltd Profit & Loss

Last Updated: July 10, 2024, 5:21 pm

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales4,0215,0126,0056,5637,5629,0799,0749,86510,64110,94412,30512,99012,124
Expenses3,3063,9974,9145,3486,1257,0437,4578,2808,9428,8609,97810,71210,828
Operating Profit7141,0151,0911,2141,4372,0371,6171,5861,6992,0842,3272,2781,296
OPM %18%20%18%18%19%22%18%16%16%19%19%18%11%
Other Income181111-18020-448937519195-101-449-990
Interest147160189190179237286335377353298350477
Depreciation98127217300234264302326417444487611577
Profit before tax4887396975441,0441,4911,1191,3011,0961,3821,441868-748
Tax %5%15%22%61%29%26%28%29%29%30%31%57%
Net Profit4646285462097431,109804925776970994377-622
EPS in Rs17.0222.8919.997.7226.3339.2928.4932.7827.5034.3833.3710.53-25.22
Dividend Payout %3%0%0%26%8%5%7%6%9%7%7%24%

Glenmark Pharmaceuticals Ltd Profit & Loss Yearly Chart

Glenmark Pharmaceuticals Ltd Growth

Compounded Sales Growth
10 Years:7%
5 Years:4%
3 Years:3%
TTM:-9%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:%
TTM:-654%
Stock Price CAGR
10 Years:8%
5 Years:27%
3 Years:32%
1 Year:77%
Return on Equity
10 Years:7%
5 Years:1%
3 Years:-5%
Last Year:-32%

Last Updated: July 24, 2024, 5:46 pm

Glenmark Pharmaceuticals Ltd Balance Sheet

Last Updated: July 10, 2024, 5:21 pm

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital27272727282828282828282828
Reserves2,3752,7362,9561,7563,6014,4645,1355,5776,0427,0369,0589,4469,299
Borrowings2,2442,7653,2673,8003,9884,7244,6394,4494,8694,9863,9624,6275,182
Other Liabilities1,0871,4662,1762,7262,5752,5482,7933,2353,7293,5244,0035,2285,498
Total Liabilities5,7336,9948,4278,30910,19311,76412,59513,28914,66815,57517,05219,32920,006
Fixed Assets2,2232,8223,0912,0152,5942,7553,0303,6705,0295,1295,8876,2025,531
CWIP263654775437081,1221,3991,2221,3821,0101,2511,221
Investments00017171615302525504545
Other Assets3,2484,1665,3315,7997,0398,2858,4298,1908,3939,04010,10511,83013,210
Total Assets5,7336,9948,4278,30910,19311,76412,59513,28914,66815,57517,05219,32920,006

Glenmark Pharmaceuticals Ltd Reserves and Borrowings Chart

Glenmark Pharmaceuticals Ltd Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity 6488544823456571,6481,3241,3921,1311,109625-265
Cash from Investing Activity -558-566-712-950-1,001-1,003-883-774-662-316-5154,561
Cash from Financing Activity 195-98199699543-468-739-445-442-520-77-3,906
Net Cash Flow285190-3193199177-2971742827232389

Glenmark Pharmaceuticals Ltd Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days11913114012097948183869211557
Inventory Days194191247249299244244211230208240208
Days Payable239279379308243225241210226190192210
Cash Conversion Cycle754386115211385849011016256
Working Capital Days9483668913311176699610011132
ROCE %18%15%16%19%21%15%15%14%15%16%14%

Glenmark Pharmaceuticals Ltd Financial Efficiency Indicators Chart

Glenmark Pharmaceuticals Ltd Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters46.65%46.65%46.65%46.65%46.65%46.65%46.65%46.65%46.65%46.65%46.65%46.65%
FIIs25.93%24.18%24.12%24.23%23.14%23.19%22.47%25.51%24.79%23.71%21.38%20.98%
DIIs9.03%10.86%10.96%10.50%10.90%10.69%10.40%9.10%10.31%10.92%13.36%13.93%
Government0.00%0.00%0.00%0.00%0.04%0.04%0.04%0.04%0.04%0.04%0.04%0.04%
Public18.40%18.31%18.27%18.63%19.27%19.45%20.46%18.70%18.21%18.70%18.58%18.42%
No. of Shareholders3,29,8703,17,3833,10,5163,12,4733,13,5403,00,1062,85,4612,36,9082,32,6852,09,9311,99,4511,92,630

Glenmark Pharmaceuticals Ltd Shareholding Pattern Chart

No. of Glenmark Pharmaceuticals Ltd Shareholders

Glenmark Pharmaceuticals Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
HDFC Mid-Cap Opportunities Fund - Regular Plan5,677,6000.85442.82713,4002024-07-24695.85%
Aditya Birla Sun Life Flexi Cap Fund5,200,6982.24405.63713,4002024-07-24629%
Kotak Equity Arbitrage Fund - Regular Plan1,353,5750.34105.57713,4002024-07-2489.74%
Aditya Birla Sun Life Midcap Fund1,311,6662.21102.3713,4002024-07-2483.86%
Motilal Oswal ELSS Tax Saver Fund1,000,0002.8378713,4002024-07-2440.17%
ICICI Prudential India Opportunities Fund858,7990.4966.98713,4002024-07-2420.38%
Tata Arbitrage Fund772,1250.7560.22713,4002024-07-248.23%
Invesco India Arbitrage Fund764,1500.5859.6713,4002024-07-247.11%
ICICI Prudential Equity - Arbitrage Fund738,0500.3657.56713,4002024-07-243.46%
HDFC Arbitrage Fund - Regular Plan713,4000.6955.64713,4002024-07-240%

Glenmark Pharmaceuticals Ltd ROCE Trend

Glenmark Pharmaceuticals Ltd EPS Trend

Glenmark Pharmaceuticals Ltd Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue1.001.001.001.001.00
Basic EPS (Rs.)-53.2210.5333.3734.3827.50
Diluted EPS (Rs.)-53.2210.5333.3734.3827.50
Cash EPS (Rs.)-30.1835.0452.4650.1042.28
Book Value[Excl.RevalReserv]/Share (Rs.)278.09348.70334.48250.36215.12
Book Value[Incl.RevalReserv]/Share (Rs.)278.09348.70334.48250.36215.12
Revenue From Operations / Share (Rs.)418.62460.36436.08387.85377.11
PBDIT / Share (Rs.)72.1391.9788.1475.6565.84
PBIT / Share (Rs.)51.5070.3170.8959.9351.05
PBT / Share (Rs.)1.2930.7851.0848.9938.84
Net Profit / Share (Rs.)-50.8013.3735.2134.3827.50
NP After MI And SOA / Share (Rs.)-53.2110.5333.3734.3827.50
PBDIT Margin (%)17.2219.9720.2119.5017.45
PBIT Margin (%)12.3015.2716.2515.4513.53
PBT Margin (%)0.306.6811.7112.6310.30
Net Profit Margin (%)-12.132.908.078.867.29
NP After MI And SOA Margin (%)-12.712.287.658.867.29
Return on Networth / Equity (%)-19.133.1310.3613.7312.78
Return on Capital Employeed (%)17.0113.8416.1314.8313.64
Return On Assets (%)-10.451.535.516.215.28
Long Term Debt / Equity (X)0.000.400.280.550.66
Total Debt / Equity (X)0.120.450.400.660.73
Asset Turnover Ratio (%)0.700.710.420.420.41
Current Ratio (X)1.281.961.771.751.65
Quick Ratio (X)0.841.371.231.211.13
Inventory Turnover Ratio (X)1.151.311.851.851.46
Dividend Payout Ratio (NP) (%)0.0023.737.497.278.76
Dividend Payout Ratio (CP) (%)0.007.764.934.995.70
Earning Retention Ratio (%)0.0076.2792.5192.7391.24
Cash Earning Retention Ratio (%)0.0092.2495.0795.0194.30
Interest Coverage Ratio (X)3.947.428.346.044.92
Interest Coverage Ratio (Post Tax) (X)-0.804.275.213.622.97
Enterprise Value (Cr.)26350.4516364.2715087.8616656.129188.07
EV / Net Operating Revenue (X)2.231.261.231.520.86
EV / EBITDA (X)12.956.316.077.804.95
MarketCap / Net Operating Revenue (X)2.291.011.011.200.54
Retention Ratios (%)0.0076.2692.5092.7291.23
Price / BV (X)3.441.381.371.860.95
Price / Net Operating Revenue (X)2.291.011.011.200.54
EarningsYield-0.050.020.070.070.13

Glenmark Pharmaceuticals Ltd Profitability Ratios (%)

Glenmark Pharmaceuticals Ltd Liquidity Ratios

Glenmark Pharmaceuticals Ltd Liquidity Ratios (%)

Glenmark Pharmaceuticals Ltd Interest Coverage Ratios (%)

Glenmark Pharmaceuticals Ltd Valuation Ratios

Fair Value

Fair Value: 1,349.33

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Overvalued: 5.38% compared to the current price 1426

Default values used*: Deafault value of 15 for Stock P/E is used

Intrinsic Value: 608.26

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Overvalued: 57.34% compared to the current price 1426

Default values used*: Deafault value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -54.92%

*Investments are subject to market risks

Strength and Weakness of Glenmark Pharmaceuticals Ltd Stock

StrengthWeakness
  1. The company has higher reserves (5,468.92 cr) compared to borrowings (3,942.25 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (8.54 cr) and profit (199.62 cr) over the years.
  1. The stock has a low average ROCE of 14.83%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 88.33, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 86.58, which may not be favorable.

FAQ

What is the latest fair value of Glenmark Pharmaceuticals Ltd?

The latest fair value of Glenmark Pharmaceuticals Ltd is ₹1349.33.

What is the Market Cap of Glenmark Pharmaceuticals Ltd?

The Market Cap of Glenmark Pharmaceuticals Ltd is 40,244 Cr..

What is the current Stock Price of Glenmark Pharmaceuticals Ltd as on 25 July 2024?

The current stock price of Glenmark Pharmaceuticals Ltd as on 25 July 2024 is 1,426.

What is the High / Low of Glenmark Pharmaceuticals Ltd stocks in FY 2024?

In FY 2024, the High / Low of Glenmark Pharmaceuticals Ltd stocks is 1,448/702.

What is the Stock P/E of Glenmark Pharmaceuticals Ltd?

The Stock P/E of Glenmark Pharmaceuticals Ltd is .

What is the Book Value of Glenmark Pharmaceuticals Ltd?

The Book Value of Glenmark Pharmaceuticals Ltd is 278.

What is the Dividend Yield of Glenmark Pharmaceuticals Ltd?

The Dividend Yield of Glenmark Pharmaceuticals Ltd is 0.18 %.

What is the ROCE of Glenmark Pharmaceuticals Ltd?

The ROCE of Glenmark Pharmaceuticals Ltd is 12.4 %.

What is the ROE of Glenmark Pharmaceuticals Ltd?

The ROE of Glenmark Pharmaceuticals Ltd is 32.3 %.

What is the Face Value of Glenmark Pharmaceuticals Ltd?

The Face Value of Glenmark Pharmaceuticals Ltd is 1.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Glenmark Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE